Literature DB >> 34206631

An Effective and Safe Enkephalin Analog for Antinociception.

K K DurgaRao Viswanadham1, Roland Böttger1, Lukas Hohenwarter1, Anne Nguyen1, Elham Rouhollahi1, Alexander Smith1, Yi-Hsuan Tsai2, Yuan-Yu Chang3, Christopher Llynard Ortiz2,4,5, Lee-Wei Yang2,6, Liliana Jimenez1, Siyuan Li1, Chan Hur1, Shyh-Dar Li1.   

Abstract

Opioids account for 69,000 overdose deaths per annum worldwide and cause serious side effects. Safer analgesics are urgently needed. The endogenous opioid peptide Leu-Enkephalin (Leu-ENK) is ineffective when introduced peripherally due to poor stability and limited membrane permeability. We developed a focused library of Leu-ENK analogs containing small hydrophobic modifications. N-pivaloyl analog KK-103 showed the highest binding affinity to the delta opioid receptor (68% relative to Leu-ENK) and an extended plasma half-life of 37 h. In the murine hot-plate model, subcutaneous KK-103 showed 10-fold improved anticonception (142%MPE·h) compared to Leu-ENK (14%MPE·h). In the formalin model, KK-103 reduced the licking and biting time to ~50% relative to the vehicle group. KK-103 was shown to act through the opioid receptors in the central nervous system. In contrast to morphine, KK-103 was longer-lasting and did not induce breathing depression, physical dependence, and tolerance, showing potential as a safe and effective analgesic.

Entities:  

Keywords:  analgesics; dependence; enkephalin; pain; respiratory suppression; tolerance

Year:  2021        PMID: 34206631     DOI: 10.3390/pharmaceutics13070927

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  65 in total

1.  The opioid peptide analogue biphalin induces less physical dependence than morphine.

Authors:  M Yamazaki; T Suzuki; M Narita; A W Lipkowski
Journal:  Life Sci       Date:  2001-07-20       Impact factor: 5.037

2.  Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines.

Authors:  N B EDDY; D LEIMBACH
Journal:  J Pharmacol Exp Ther       Date:  1953-03       Impact factor: 4.030

Review 3.  Strategies to improve plasma half life time of peptide and protein drugs.

Authors:  M Werle; A Bernkop-Schnürch
Journal:  Amino Acids       Date:  2006-04-20       Impact factor: 3.520

4.  Preparation and evaluation at the delta opioid receptor of a series of linear leu-enkephalin analogues obtained by systematic replacement of the amides.

Authors:  Kristina Rochon; Arnaud Proteau-Gagné; Philippe Bourassa; Jean-François Nadon; Jérome Côté; Véronique Bournival; Fernand Gobeil; Brigitte Guérin; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2013-05-20       Impact factor: 4.418

5.  Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.

Authors:  T Uchiyama; A Kotani; H Tatsumi; T Kishida; A Okamoto; N Okada; M Murakami; T Fujita; Y Fujiwara; Y Kiso; S Muranishi; A Yamamoto
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

6.  Lipid solubility and drug penetration of the blood brain barrier.

Authors:  W H Oldendorf
Journal:  Proc Soc Exp Biol Med       Date:  1974-12

7.  Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia.

Authors:  Lisa Godfrey; Antonio Iannitelli; Natalie L Garrett; Julian Moger; Ian Imbert; Tamara King; Frank Porreca; Ramesh Soundararajan; Aikaterini Lalatsa; Andreas G Schätzlein; Ijeoma F Uchegbu
Journal:  J Control Release       Date:  2017-11-27       Impact factor: 9.776

8.  Antinociceptive profile of biphalin, a dimeric enkephalin analog.

Authors:  P J Horan; A Mattia; E J Bilsky; S Weber; T P Davis; H I Yamamura; E Malatynska; S M Appleyard; J Slaninova; A Misicka
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

Review 9.  Evolution of proteolytic enzymes.

Authors:  H Neurath
Journal:  Science       Date:  1984-04-27       Impact factor: 47.728

10.  Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum.

Authors:  Roland Böttger; Ralf Hoffmann; Daniel Knappe
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.